Trade with Eva: Analytics in action >>

Wednesday, June 3, 2020

Campbell Soup Co. (CPB) reported earnings on Wed 3 June 20 (b/o)

** charts after earnings **




 





Campbell Soup beats by $0.29, misses on revs; raises FY20 guidance

  • Reports Q3 (Apr) earnings of $0.83 per share, excluding non-recurring items, $0.29 better than the S&P Capital IQ Consensus of $0.54; revenues rose 14.6% year/year to $2.24 bln vs the $2.26 bln S&P Capital IQ Consensus.
  • In the third quarter of fiscal 2020, Campbell achieved $30 million in savings under its multi-year cost savings program, inclusive of Snyder's-Lance synergies, bringing total program-to-date savings to $680 million. Year-to-date savings were $120 million through the first nine months of fiscal 2020. As previously announced, the company expects to deliver cumulative annualized savings of $850 million by the end of fiscal 2022.
  • Co issues guidance for FY20, raises EPS to $2.87-2.92 from $2.55-2.60, excluding non-recurring items, vs. $2.89 S&P Capital IQ Consensus; sees FY20 revs of +5.5-6.0% from (1%) to 1% to $8.55-8.63 bln vs. $8.63 bln S&P Capital IQ Consensus.
  • Tuesday, June 2, 2020

    -=MoneyGram (MGI) : takeover talks with Western Union (WU)


    According to a Bloomberg report, Western Union has already made a takeover offer for MoneyGram, but no decision has been made and Western Union could choose to proceed without a deal.

    MGI is the second largest money transfer player with ~350K agents around the world, and a fast growing self-service (kiosk) and online presence which are 15% of money transfer revenues.

    However the company has struggled recently, with 1Q revenues of $290.9M declining 8% y/y, and April transactions down 19% y/y. This was despite the fact that April saw significant growth in digital transaction with a 75% increase.

    Monday, June 1, 2020

    Long trade : Amyris (AMRS) +40% (6/10)

    • May 29: #7, 11, 29, 30 ; vol.2.0M


     


    Friday, May 29, 2020

    This week's biggest % winners & losers: May 25 - 29, 20 (wk 22)

    This week's biggest % gainers/losers The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume)

    This week's top % gainers
    • Healthcare: ADAP (11.07 +91.85%), SLP (50.67 +29.52%)
    • Materials: SID (1.89 +28.57%)
    • Industrials: TGI (7.49 +34.95%), FLY (8.28 +34.2%), CAR (21.53 +28.77%)
    • Consumer Discretionary: PRTY (1.29 +93.49%), ASNA (1.67 +34.68%), LOVE (18.31 +32.59%), MIK (3.86 +31.74%)
    • Information Technology: STNE (31.68 +29.52%)
    • Energy: SMLP (1.31 +50.57%), NBR (37.06 +41.67%), HLX (3.36 +30.23%)
    • Utilities: SBS (10.03 +28.26%)

    This week's top % losers
    • Healthcare: MGNX (19.24 -24.16%), ATRA (11.5 -22.35%), IOVA (32.09 -21.73%), IRWD (9.73 -18.71%), BCRX (4.5 -17.52%), NTLA (17.51 -16.58%), MNK (2.82 -16.32%), ALLK (65 -15.1%), TGTX (18.65 -14.61%)
    • Materials: NG (9.56 -17.37%)
    • Industrials: HTZ (1.00 -64.79%)
    • Financials: FG (8.34 -21.1%), SUPV (1.97 -18.6%), BMA (17.16 -17.5%), GGAL (8.01 -15.77%)
    • Energy: GLOP (4.39 -15.25%)

    Adaptimmune Therapeutics (ADAP) : positive data on experimental cell therapy

    • The company said that trials of its SPEAR T-cell therapy showed a 50% response rate in patients with synovial sarcoma. The company also reported confirmed responses in lung cancer patients, and had previously reported confirmed responses in head and neck cancer patients. 


     







    Adaptimmune Therapeutics presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting


  • New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy.
  • Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned in the US in 2022.
  • Phase 2 trial combining ADP-A2M4 with pembrolizumab in head and neck cancer (SPEARHEAD-2) will be the first time a SPEAR T-cell therapy is used in sequence with first line systemic therapy.
  • The company also announced new responses in the SURPASS trial, confirming the potential for SPEAR T-cell therapies targeting MAGE-A4 to treat a broad range of cancers in addition to sarcoma. These data further support the rationale for two new Phase 2 trials -- SPEARHEAD-2 in head and neck cancer, which will begin later this year, and a second trial in esophagogastric junction (EGJ) cancer planned for 1H 2021.
  • The SURPASS trial (a Phase 1 trial with ADP-A2M4CD8) will focus on lung, EGJ, head and neck, and bladder cancers.
  • Confirmed complete response in a patient with liver cancer in the Phase 1 ADP-A2AFP trial (reported as partial response in January).